TrialsgrambetaRCTs are beautiful
TCT 2026Presentado dom, 1 nov · 11:29 GMT-8Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetTodos los ensayos Late-Breaking →

HD-PCI

2026

A Randomized Trial of Higher vs. Lower Dose Heparin for PCI (HD-PCI)

In patients undergoing elective PCI, a higher-dose unfractionated heparin policy did not reduce death, myocardial infarction or target vessel revascularisation at 30 days, or change major bleeding, compared with a lower-dose heparin policy.

Resultado

Eficacia: Death, myocardial infarction or target vessel revascularisation within 30 daysHR 1,29 (IC del 95% 0,89-1,87)

Seguridad: Major bleedingHR 1,03 (IC del 95% 0,70-1,52)

Por debajo de 1 a favor de a higher-dose unfractionated heparin policy, por encima de 1 a favor de a lower-dose heparin policy.

Tasas de eventos a higher-dose unfractionated heparin policy 1,2% vs. a lower-dose heparin policy 1,0% (death, myocardial infarction or target vessel revascularisation within 30 days)

También se informa: An activated clotting time was recorded in 39.6% of procedures.

Publicación original
Subtema
Periprocedural anticoagulation
Diseño
Cluster-randomised crossover trial of hospital-wide heparin policies for elective PCI (Population Health Research Institute, Canada). Each hospital alternates between a 100 U/kg and a 70 U/kg bolus of unfractionated heparin; outcomes come from linked PCI registries
Incluidos
11.619 pacientes
Fuente
Jolly S, et al. Presented at TCT 2026, 1 November. Reported by TCTMD (CRF). Not yet published.

Discusión y crítica

In a large cluster-crossover trial of elective PCI, a higher-dose heparin policy did not reduce 30-day ischaemic events or change major bleeding, and the source reports that the confidence interval excluded the benefit the trial was powered for. Follow-up was limited to 30 days, event rates were low, and centres rather than patients were randomised, so the trial compares hospital policies rather than individual dosing. The report gives hazard ratios without P values and does not describe blinding, adherence to the assigned policy or a net clinical outcome. These figures come from a news report of the presentation, not a peer-reviewed paper.